HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and maintained a price target of $94.
August 07, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on ANI Pharmaceuticals and maintained a price target of $94.
The reiteration of a Buy rating and maintenance of a $94 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100